Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced ...

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced ...

Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with ...

43rd Annual J.P. Morgan Healthcare Conference – Company Presentation Date: Wednesday, January 15, 2025 Time: 3:45 p.m. - 4:25 p.m. PT Location: The Westin St. Francis Hotel, San Francisco, CA ...

The J.P. Morgan Healthcare Conference attracts thousands of attendees each year from the provider, insurance, digital health ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

Then, next week, Nvidia is on the road again at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, which ...

FOSTER CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage ...

Aktis Oncology, an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for large patient populations not addressed by existing platform technologies, ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), will present at the 43rd Annual J.P. Morgan Healthcare ...